ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Sponsor
Eli Lilly and Company (Industry)
Overall Status
Approved for marketing
CT.gov ID
NCT00040625
Collaborator
(none)
6
Study Details
Study Description
Brief Summary
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
-
Prior chemotherapy for your disease is allowed
-
Measurable lesion is not required
-
Have a adequate performance status
-
Sign an informed consent form
Exclusion Criteria:
-
You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
-
You are excluded from this trial if you have received radiation within the previous 2 weeks
-
You are excluded from this trial if you are a candidates for curative surgery
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | Basking Ridge | New Jersey | United States | |
| 2 | For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Porto Alegre | RS | Brazil | |
| 3 | For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Sao Paulo | Brazil | ||
| 4 | "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." | Cairo | Egypt | ||
| 5 | For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Cairo | Egypt | ||
| 6 | For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Jeddah | Saudi Arabia |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00040625
Other Study ID Numbers:
- 6093
- H3E-US-JMFE
First Posted:
Jul 4, 2002
Last Update Posted:
Mar 15, 2007
Last Verified:
Mar 1, 2007